An Incisive, In-depth Analysis on the Liquid Biopsy Market
This study offers a comprehensive, 360 degree analysis on the Liquid Biopsy market, bringing to fore insights that can help stakeholders identify the opportunities as well as challenges. It tracks the global Liquid Biopsy market across key regions, and offers in-depth commentary and accurate quantitative insights. The study also includes incisive competitive landscape analysis, and provides key recommendations to market players on winning imperatives and successful strategies.
Liquid biopsy is an advanced cancer diagnostic test that uses biofluids such as blood, CSF, plasma and urine for detecting cancer. The test can be used to detect cancer in early stages. It is a non-invasive diagnostic test that uses circulating nucleic acids, circulating tumour cells (CTC) and exosomes as a biomarker for diagnosis of cancer. In the body, aforementioned biomarkers are released into different body fluids by cancer cells. The test requires blood, urine and cerebral spinal fluid (CSF) samples for diagnosis of various cancers. Among all samples, blood sample is widely used for diagnosis of various cancers such as lung cancer, breast cancer and leukemia. Urine and CSF samples are used for diagnosis of prostate cancer and brain cancer respectively.
Market Value and Forecast
Global liquid biopsy market revenues are projected to expand at a CAGR of 21.7% during the forecast period 2016-2026 and a reach value of US$ 2,893.7 million by the end of 2026.
Growth of the global liquid biopsy market is mainly driven by increasing prevalence of cancer globally. Increasing prevalence of various cancers such as lung cancer, breast cancer and prostate cancer is expected to drive growth of the liquid biopsy test market over the forecast period. Other prominent growth factors include increasing preference of oncologists towards non-invasive diagnostic procedure for detecting cancer. However, cost and lower awareness regarding liquid biopsy tests are the major factor expected to restrain growth of global liquid biopsy market over the forecast period.
FDA approvals for various non-invasive diagnostic tests to detect cancer is set to define the regulatory landscape for liquid biopsy tests. Companies in the liquid biopsy market space are expected to invest more on test kits and cost containment procedures to provide innovative diagnostic solutions to the oncologists and physicians for detecting metastasis.
Market Segmentation by Marker Type
Based on marker type, the market has been segmented into circulating tumour Cells (CTCs), ctNA circulating tumour nucleic acids (ctNA), and exosomes.
Market Segmentation, by Sample Type
Based on sample type, the market has been segmented into blood, urine, and others (plasma, saliva, Cerebrospinal fluid). Blood sample type segment, is expected to create significant incremental opportunity in global liquid biopsy market over the forecast period.
Market Segmentation, by Disease Indication
Based on disease indication, the market has been segmented into lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, colorectal, leukemia and others. Lung cancer, disease indication segment currently accounts for highest revenue as compared to other segments in the global liquid biopsy market. Whereas breast cancer and colorectal cancer, disease indication segments have been anticipated to contribute significant revenue in global liquid biopsy market over the forecast period.
Market Segmentation, by End User
Based on end user type, the market has been segmented into hospitals, cancer institutes, academic institutes and diagnostic centres. Cancer institute is the largest end user segment in terms of revenues and is expected to create significant incremental opportunity in global liquid biopsy market over the forecast period.
The global liquid biopsy market has been segmented into seven major regions: North America, Latin America, Western Europe, Eastern Europe, Asia Pacific excluding Japan (APEJ), Japan, and Middle East & Africa (MEA). In terms of value, North America is estimated to be the dominant market in 2016, which is expected to expand at a CAGR of 21.3% over the forecast period. APEJ is estimated to be the fastest growing markets in terms of revenue growth. APEJ liquid biopsy market is expected to register a CAGR of 25.5% over the forecast period. Lung cancer disease indication segment in the APEJ liquid biopsy market is expected to register a CAGR of 22.0% over the forecast period, with growth driven by increasing prevalence of lung cancer in the region.
Some key players in the global liquid biopsy market identified in this report are BIOCEPT, INC., Qiagen N.V., Trovagene, Inc., Janssen Global Services, LLC, MDxHealth SA, Natera, Inc., F. Hoffmann-La Roche Ltd., Silicon Biosystems, Pathway Genomics Corporation, Sysmex Corporation. The report also identifies company-specific strategies related to market consolidation initiatives and analysis of their specific strengths, weaknesses, opportunities and threats.
This report by Future Market Insights (FMI) examines the ‘Liquid Biopsy Market’ for the period 2016–2026. The primary objective of the report is to offer updates and information related to market opportunities in the global liquid biopsy market.
The global liquid biopsy market report begins by defining liquid biopsy and various types of markers used in liquid biopsy. It is followed by an overview of market dynamics of the global liquid biopsy market, which includes FMI’s analysis of key trends, drivers, restraints and opportunities, and reimbursement scenario that is influencing the growth of the liquid biopsy market. It also includes an insight into case-studies and product pipeline. Impact analysis of key growth drivers and restraints based on a weighted average model have been included in the global liquid biopsy market report after detailed analysis of individual regions to better equip readers with meaningful insights on ongoing developments in the oncology market.
The primary factors fuelling demand for liquid biopsy diagnostic tests are growing incidences of lung, gastrointestinal and breast cancer. Other factors driving demand for liquid biopsy tests are increasing inclination of oncologists and physician to opt for non-invasive diagnostic procedures, reluctance of the patients to go painful biopsies and increase in the demand of personalized medicine. Whereas increasing number of test launches and entry of regional players also drives the market for liquid biopsy tests. However, a primary factor hampering growth of the liquid biopsy market is its penetration owing lower awareness of blood tests to detect cancer.
Based on market type, the market has been segmented into circulating tumour cells (CTCs), Circulating tumour Nucleic Acids (ctNA) and exosomes. A detailed analysis has been provided for these segment in terms of market size, Y-o-Y growth rate, absolute $ opportunity and BPS analysis.
Based on sample type, the market has been segmented into blood, urine and others (plasma, saliva, CSF). Our analysis predicts that biopsies through blood samples would increase at a very fast pace, increasing the number of blood diagnostic test to detect cancer is expected to contribute significantly to increasing demand for liquid biopsies the forecast period.
Based on the disease indication the liquid biopsy market has been segmented into lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, colorectal cancer, leukemia and others. Lung cancer is expected to expand at a higher CAGR, due to increasing prevalence of lung cancer over the forecast period. Further, based on end-user segmentation, the market is segmented into hospitals, cancer institutes, academic institutes and diagnostic centres. Increasing commercialization of liquid biopsy test is expected to increase the revenue generation of liquid biopsies from hospitals and diagnostic centres surgery. This trend is expected to be particularly prominent in countries where access to healthcare services is increasing especially in APEJ
The next section of the report highlights liquid biopsy market by region and provides market outlook for 2016–2026. The report also discusses key regional trends contributing to the revenue growth of the liquid biopsy tests worldwide, as well as analyses the impact of drivers and restraints in each region. Key regions assessed in this report include North America, Latin America, Western Europe, Eastern Europe, Asia Pacific Excluding Japan (APEJ), Japan and Middle East & Africa (MEA).
The above sections—by marker type, sample type, disease indication, end users and region—evaluate the present scenario and growth prospects of the liquid biopsy tests market for 2016–2026. We have considered 2015 as the base year and provided data for the forecast period, i.e., 2016–2026.
To ascertain liquid biopsy tests market size, we have also considered revenue generated by companies in liquid biopsy market space. The forecast presented here assesses the total revenue by value across the liquid biopsy market. In order to offer an accurate forecast, we started by sizing up the current market, which forms the basis of how the liquid biopsy market is expected to develop in the future. Given the characteristics of the market, we triangulated the outcome of three different types of analysis based on supply side, downstream industry demand, and the economic envelope.
In addition, it is imperative to note that in an ever-fluctuating global economy, we not only conduct forecasts in terms of CAGR, but also analyse it based on key parameters such as year-on-year (Y-o-Y) growth rates to understand the predictability of the market, and to identify the right opportunities across the global liquid biopsy market.
The liquid biopsy market segments in terms of marker type, sample type, disease indication, end user, and regions. These segments are analysed in terms of Basis Point Share (BPS) to understand individual segment’s relative contributions to market growth. This detailed level of information is important for identifying various key trends in the liquid biopsy market.
Another key feature of this report is the analysis of key segments in terms of absolute dollar opportunity. This is overlooked while forecasting the market. However, absolute dollar opportunity is critical for assessing the level of opportunity that a provider can look to achieve, as well as to identify potential resources from a sales and delivery perspective, in the global liquid biopsy market.
To understand key growth segments in terms of growth and adoption for liquid biopsy tests globally, Future Market Insights developed the liquid biopsy market ‘Attractiveness Index’. The resulting index is expected to help providers identify real market opportunities in the overall oncology market.
In the final section of the report on the global liquid biopsy market, ‘Competitive Landscape’ is included to provide report audiences with a dashboard view, based on categories of test developers in the liquid biopsy market space and key differentiators. Key categories of providers covered in the report are companies developing liquid biopsy tests. This section is primarily designed to provide clients with an objective and detailed comparative assessment of key providers specific to a market segment in the liquid biopsy value chain and the potential players for the same. Report audiences can gain segment-specific company insights to identify and evaluate key competitors based on in-depth assessment of capabilities and successes in liquid biopsy marketplace.
Detailed profiles of the liquid biopsy tests developing companies are also included in the scope of the report to evaluate their long- and short-term strategies, key offerings, SWOT analysis, and recent developments in the global liquid biopsy market.
Key competitors covered in terms of liquid biopsy test developing companies BIOCEPT, INC., Qiagen N.V., Trovagene, Inc., Janssen Global Services, LLC, MDxHealth SA, Natera, Inc., F. Hoffmann-La Roche Ltd., Silicon Biosystems, Pathway Genomics Corporation, Sysmex Corporation.
Key Segments Covered
- By Marker Type
- CTCs (Circulating tumour Cells)
- ctNA (Circulating tumour Nucleic Acids)
- By Sample Type
- Others (Plasma, Saliva, CSF)
- By Disease Indication
- Lung Cancer
- Gastrointestinal Cancer
- Prostate Cancer
- Breast Cancer
- Colorectal Cancer
- By End-User
- Cancer Institutes
- Academic Institutes
- Diagnostic Centers
Key Regions/Countries Covered
- North America
- Latin America
- Rest of Latin America
- Western Europe
- Rest of Western Europe
- Eastern Europe
- Rest of Eastern Europe
- Asia Pacific Ex. Japan (APEJ)
- Australia and New Zealand
- Rest of APAC
- Middle East & Africa
- South Africa
- Rest of MEA
- BIOCEPT, INC.
- Qiagen N.V.
- Trovagene, Inc.
- Janssen Global Services, LLC
- MDxHealth SA
- Natera, Inc.
- Hoffmann-La Roche Ltd.
- Silicon Biosystems
- Pathway Genomics Corporation
- Sysmex Corporation
Liquid Biopsy Market Reports - Table of Contents
1. Executive Summary
2. Assumptions and Acronyms
3. Research Methodology